SS Innovations International (NASDAQ: SSII) announced on October 14, 2026, that it submitted a response to the U.S. Food and Drug Administration (FDA) on October 5, 2026, addressing the agency's request for additional information regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal.
The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027. This regulatory milestone is critical for SS Innovations as it seeks to introduce the SSi Mantra system to the U.S. market, one of the largest and most competitive markets for surgical robotics. A successful FDA clearance would not only validate the technology but also position the company to compete with established players in the U.S. surgical robotics space.
The SSi Mantra system is a modular, multi-arm surgical robot with advanced features such as 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient information display. It also includes a virtual real-time image of the robotic patient-side arm carts and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console offers portability and telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries, and has been clinically validated in India for more than 190 different types of surgical procedures.
According to the company, the SSi Mantra is designed to make robotic surgery affordable and accessible to a larger segment of the global population. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. For more information, visit ssinnovations.com or LinkedIn.
The FDA's request for additional information is a common step in the regulatory process, and the company's prompt response with comprehensive data demonstrates its commitment to addressing the agency's concerns. The bridging study conducted at Hospital Internacional de Colombia, a Mayo Clinic Care Network member, adds credibility to the clinical evidence, as it was performed in a setting with high standards of care. The expanded human clinical and human factors validation study further supports the system's safety and usability.
If the FDA completes its review in the first quarter of 2027 as anticipated, SS Innovations could begin commercializing the SSi Mantra in the U.S. shortly thereafter. This would mark a significant expansion for the company, which currently has a strong presence in India but limited reach in Western markets. The U.S. surgical robotics market is dominated by Intuitive Surgical's da Vinci system, but there is growing demand for cost-effective alternatives. SS Innovations' focus on affordability and accessibility could disrupt the market by offering a lower-cost option to hospitals that cannot afford the da Vinci system.
However, the company faces risks and uncertainties, as noted in its forward-looking statements. These include regulatory delays, competition, and the challenges of scaling up manufacturing and sales in a new market. Investors and industry observers will be watching closely to see if SS Innovations can successfully navigate the FDA process and execute its U.S. market entry strategy.
For the latest news and updates relating to SSII, visit the company's newsroom at https://ibn.fm/SSII. The full press release can be viewed at https://ibn.fm/A6dJ8.
